In a filing, Prelude Therapeutics Inc revealed its Chief Chemistry Officer Combs Andrew acquired Company’s shares for reported $82002.0 on Dec 23 ’24. In the deal valued at $1.37 per share,60,000 shares were bought. As a result of this transaction, Combs Andrew now holds 377,623 shares worth roughly $0.46 million.
Then, Combs Andrew bought 3,075 shares, generating $3,536 in total proceeds. Upon buying the shares at $1.15, the Chief Chemistry Officer now owns 317,623 shares.
Before that, Lim Bryant David bought 25,000 shares. Prelude Therapeutics Inc shares valued at $22,638 were divested by the CLO, Interim CFO, Corp Sec. at a price of $0.91 per share. As a result of the transaction, Lim Bryant David now holds 27,400 shares, worth roughly $33154.0.
H.C. Wainwright upgraded its Prelude Therapeutics Inc [PRLD] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Barclays’s analysts, who decreased its forecast for the stock in mid June from “an Equal weight” to “an Underweight”. JMP Securities began covering PRLD with “Mkt outperform” recommendation on March 13, 2024. H.C. Wainwright revised its rating on February 20, 2024. It rated PRLD as “a Neutral” which previously was an “a Buy”.
Price Performance Review of PRLD
On Monday, Prelude Therapeutics Inc [NASDAQ:PRLD] saw its stock fall -9.70% to $1.21. Over the last five days, the stock has lost -6.92%. Prelude Therapeutics Inc shares have fallen nearly -71.66% since the year began. Nevertheless, the stocks have fallen -70.84% over the past one year. While a 52-week high of $6.80 was reached on 08/14/24, a 52-week low of $0.80 was recorded on 12/16/24. SMA at 50 days reached $1.1632, while 200 days put it at $3.4187.
Levels Of Support And Resistance For PRLD Stock
The 24-hour chart illustrates a support level at 1.0940, which if violated will result in even more drops to 0.9780. On the upside, there is a resistance level at 1.3520. A further resistance level may holdings at 1.4940. The Relative Strength Index (RSI) on the 14-day chart is 53.88, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.2558, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 47.90%. Stochastics %K at 65.55% indicates the stock is a holding.
How much short interest is there in Prelude Therapeutics Inc?
A steep rise in short interest was recorded in Prelude Therapeutics Inc stocks on 2024-12-13, growing by 0.36 million shares to a total of 3.26 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 2.9 million shares. There was a rise of 11.15%, which implies that there is a positive sentiment for the stock.
